Ciphergen, OSU, Bruker Daltonics, Alfa Wassermann, Pressure BioSciences, Dyax, CSIRO, NIH | GenomeWeb
Ciphergen, OSU Research Foundation Collaborate on Dx Test for TTP
 
Ciphergen and the Ohio State University Research Foundation announced this week a collaboration to develop a diagnostic test for thrombotic thrombocytopenic purpura using the SELDI platform.
 
Under terms of the agreement, the two parties will “optimize” a SELDI-based test to measure enzyme and antibody inhibition activity and jointly conduct multi-center studies to validate the test. Financial terms of the deal were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.